Mycobacterium tuberculosis-associated immune reconstitution syndrome in solid-organ transplant recipients

Transplantation. 2013 May 15;95(9):1173-81. doi: 10.1097/TP.0b013e31828719c8.

Abstract

Background: Incidence, characteristics, and risk factors for tuberculosis (TB)-associated immune reconstitution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known.

Methods: Patients are composed of 64 consecutive SOT recipients with TB followed for 12 months. IRS was defined based on previously proposed criteria.

Results: IRS developed in 14% (9/64) of the patients, a median of 47 days after the use of anti-TB therapy. Liver versus other types of organ transplant recipients (adjusted odds ratio [OR], 6.11; 95% confidence interval [CI], 1.08-34.86), prior cytomegalovirus infection (adjusted OR, 5.65; 95% CI, 0.93-34.47), and rifampin use (adjusted OR, 4.56; 95% CI, 0.74-27) were associated with a higher risk of IRS. The presence of more than one factor (liver transplantation, cytomegalovirus infection, and rifampin use) when compared with none of these factors conferred a 19-fold increase in the risk of IRS (P=0.01). Mortality at 1 year after diagnosis was 33.3% in patients with IRS and 17.2% in those without IRS (P=0.31).

Conclusions: IRS was documented in 14% of the SOT recipients with TB. We determined clinically identifiable factors that may be useful in assessing the risk of tuberculosis-associated posttransplantation IRS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immune Reconstitution Inflammatory Syndrome / etiology*
  • Immune Reconstitution Inflammatory Syndrome / mortality
  • Immunosuppression Therapy
  • Logistic Models
  • Organ Transplantation / adverse effects*
  • Risk Factors
  • Tuberculosis / complications*